Compare NRP & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRP | IVA |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2020 |
| Metric | NRP | IVA |
|---|---|---|
| Price | $118.86 | $6.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $16.20 |
| AVG Volume (30 Days) | 51.9K | ★ 654.3K |
| Earning Date | 02-27-2026 | 09-29-2025 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.92 | N/A |
| Revenue | ★ $218,701,000.00 | $19,929,536.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $86.83 | $2.23 |
| 52 Week High | $123.40 | $7.98 |
| Indicator | NRP | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 68.99 | 54.87 |
| Support Level | $112.81 | $5.89 |
| Resistance Level | $116.85 | $7.20 |
| Average True Range (ATR) | 3.80 | 0.36 |
| MACD | -0.24 | -0.10 |
| Stochastic Oscillator | 53.97 | 24.03 |
Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. Geographically, the business activity of the group functions through the United States.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.